Ultragenyx Pharmaceutical | RARE - Selling And Administration Expenses


Ultragenyx Pharmaceutical reported $89M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 146.73M 21.82M Dec/2025
Agios Pharmaceuticals USD 42.97M 1.7M Dec/2025
Alnylam Pharmaceuticals USD 285.06M 22.47M Dec/2025
BioCryst Pharmaceuticals USD 95.78M 12.77M Dec/2025
BioMarin Pharmaceutical USD 322.21M 98.79M Dec/2025
Esperion Therapeutics USD 39.42M 456K Dec/2025
Immunic USD -0.24 0.03 Sep/2024
Insmed USD 212.48M 26.11M Dec/2025
Ionis Pharmaceuticals USD 130M 43.43M Dec/2025
Karyopharm Therapeutics USD 9.56M 17.63M Dec/2025
Kyowa Hakko Kirin JPY 43.89B 5.17B Dec/2025
MacroGenics USD 7.94M 1.96M Dec/2025
Moderna USD 308M 40M Dec/2025
Neurocrine Biosciences USD 301.8M 10.2M Dec/2025
PTC Therapeutics USD 87.2M 3.15M Dec/2025
Puma Biotechnology USD 16.82M 8.15M Sep/2024
Regeneron Pharmaceuticals USD 775M 117.2M Dec/2025
Sarepta Therapeutics USD 105.38M 28.27M Dec/2025
Ultragenyx Pharmaceutical USD 89M 2.38M Dec/2025
Vertex Pharmaceuticals USD 487M 41.9M Dec/2025
Xoma USD 11M 2.54M Jun/2024